KR20160070457A - Process for Preparing Lubiprostone and Intermediate Therefor - Google Patents
Process for Preparing Lubiprostone and Intermediate Therefor Download PDFInfo
- Publication number
- KR20160070457A KR20160070457A KR1020140177425A KR20140177425A KR20160070457A KR 20160070457 A KR20160070457 A KR 20160070457A KR 1020140177425 A KR1020140177425 A KR 1020140177425A KR 20140177425 A KR20140177425 A KR 20140177425A KR 20160070457 A KR20160070457 A KR 20160070457A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- reaction
- chemical formula
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000004519 manufacturing process Methods 0.000 title description 14
- WGFOBBZOWHGYQH-MXHNKVEKSA-N lubiprostone Chemical compound O1[C@](C(F)(F)CCCC)(O)CC[C@@H]2[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]21 WGFOBBZOWHGYQH-MXHNKVEKSA-N 0.000 title description 2
- 229960000345 lubiprostone Drugs 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 25
- 125000006239 protecting group Chemical group 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 121
- 238000006243 chemical reaction Methods 0.000 claims description 62
- 239000000126 substance Substances 0.000 claims description 39
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 21
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical group [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 15
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical group [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 12
- 238000007239 Wittig reaction Methods 0.000 claims description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical group CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 8
- 102000004882 Lipase Human genes 0.000 claims description 7
- 108090001060 Lipase Proteins 0.000 claims description 7
- 239000004367 Lipase Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 235000019421 lipase Nutrition 0.000 claims description 7
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 6
- GLYOPNLBKCBTMI-UHFFFAOYSA-N [2-chloro-2-(1-chloro-2-phenylethoxy)ethyl]benzene Chemical compound C=1C=CC=CC=1CC(Cl)OC(Cl)CC1=CC=CC=C1 GLYOPNLBKCBTMI-UHFFFAOYSA-N 0.000 claims description 6
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 claims description 6
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 claims description 6
- 150000002576 ketones Chemical class 0.000 claims description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 5
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 5
- 238000010511 deprotection reaction Methods 0.000 claims description 5
- 238000005984 hydrogenation reaction Methods 0.000 claims description 5
- 230000001590 oxidative effect Effects 0.000 claims description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 5
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical group [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 238000006722 reduction reaction Methods 0.000 claims description 4
- 239000000543 intermediate Substances 0.000 abstract description 5
- 150000002009 diols Chemical class 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 57
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000004809 thin layer chromatography Methods 0.000 description 11
- KPSZWAJWFMFMFF-UHFFFAOYSA-N hept-5-enoic acid Chemical compound CC=CCCCC(O)=O KPSZWAJWFMFMFF-UHFFFAOYSA-N 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000007810 chemical reaction solvent Substances 0.000 description 9
- 230000035484 reaction time Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- -1 1,1-difluoro-cyclopentyl Chemical group 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- MLOSJPZSZWUDSK-UHFFFAOYSA-N 4-carboxybutyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 MLOSJPZSZWUDSK-UHFFFAOYSA-N 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000010979 ruby Substances 0.000 description 6
- 229910001750 ruby Inorganic materials 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- CISDEVRDMKWPCP-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3,3-difluoroheptan-2-one Chemical compound CCCCC(F)(F)C(=O)CP(=O)(OC)OC CISDEVRDMKWPCP-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- XTUTXYBGTIFZFQ-UHFFFAOYSA-N ethyl 2,2-difluorohexanoate Chemical compound CCCCC(F)(F)C(=O)OCC XTUTXYBGTIFZFQ-UHFFFAOYSA-N 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 0 CC(OC[C@@]([C@@](C1)[C@](C2)OC1=O)[C@@]2OCO*)=O Chemical compound CC(OC[C@@]([C@@](C1)[C@](C2)OC1=O)[C@@]2OCO*)=O 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- WRQGPGZATPOHHX-UHFFFAOYSA-N ethyl 2-oxohexanoate Chemical compound CCCCC(=O)C(=O)OCC WRQGPGZATPOHHX-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 2
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical class [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- XTQFFVIVPYXWKF-BGZDPUMWSA-N CC(OC[C@H]([C@@H](C1)[C@H](C2)OC1=O)[C@@H]2O)=O Chemical compound CC(OC[C@H]([C@@H](C1)[C@H](C2)OC1=O)[C@@H]2O)=O XTQFFVIVPYXWKF-BGZDPUMWSA-N 0.000 description 1
- WGFOBBZOWHGYQH-URCPGQDYSA-N CCCCC(C(CC1)(O)O[C@H](C2)[C@H]1[C@@H](CCCCCCC(O)=O)C2=O)(F)F Chemical compound CCCCC(C(CC1)(O)O[C@H](C2)[C@H]1[C@@H](CCCCCCC(O)=O)C2=O)(F)F WGFOBBZOWHGYQH-URCPGQDYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- CPVNCBJFUQQXSU-UHFFFAOYSA-O OC(CCCC[P+](c1ccccc1)(c1ccccc1)c1ccccc1)=O Chemical compound OC(CCCC[P+](c1ccccc1)(c1ccccc1)c1ccccc1)=O CPVNCBJFUQQXSU-UHFFFAOYSA-O 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940040386 amitiza Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- OYQFTSIAUDKBCV-UHFFFAOYSA-N cyclopenta[b]furan-4-one Chemical compound O1C=CC2=C1C=CC2=O OYQFTSIAUDKBCV-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- VONWDASPFIQPDY-UHFFFAOYSA-N dimethyl methylphosphonate Chemical compound COP(C)(=O)OC VONWDASPFIQPDY-UHFFFAOYSA-N 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- QPMJENKZJUFOON-PLNGDYQASA-N ethyl (z)-3-chloro-2-cyano-4,4,4-trifluorobut-2-enoate Chemical compound CCOC(=O)C(\C#N)=C(/Cl)C(F)(F)F QPMJENKZJUFOON-PLNGDYQASA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- RTYRONIMTRDBLT-UHFFFAOYSA-N hept-5-en-2-one Chemical compound CC=CCCC(C)=O RTYRONIMTRDBLT-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
- C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
본 발명은 루비프로스톤의 제조방법 및 그에 사용되는 중간체에 관한 것이다. 본 발명에 따르면, 코리 락톤 디올에 보호기를 선택적으로 도입하여 루비프로스톤을 효율적이고 경제적으로 제조할 수 있다.The present invention relates to a process for producing rubyprostones and intermediates used therein. According to the present invention, it is possible to efficiently and economically produce rubyprostone by selectively introducing a protecting group into the coriolactone diol.
Description
본 발명은 루비프로스톤(Lubiprostone)의 제조방법 및 그를 위한 중간체에 관한 것으로, 보다 상세하게는 루비프로스톤을 효율적이고 경제적으로 제조하는 방법 및 그에 사용되는 중간체에 관한 것이다.The present invention relates to a process for producing rubyprostone and intermediates therewithin, and more particularly to a process for efficiently and economically producing rubyprostone and intermediates used therein.
15-케토프로스타글란딘 유도체인 하기 화학식 1의 루비프로스톤, 7-((1R, 3R, 6R, 7R)-3-(1,1-디플루오로펜틸)-3-히드록시-8-옥소-2-옥사바이사이클로[4.3.0]논-7-일)헵탄산은 성인의 만성 변비 치료에 사용되는 위장약인 아미티자(Amitiza®)의 활성 약학적 성분(API)이다. 15-keto-prostaglandin derivatives of formula (I) to the pro ruby stones, 7 - ((1 R, 3 R, 6 R, 7 R) -3- ( 1,1-difluoro-cyclopentyl) -3-hydroxy -8 - a-oxo-2-oxa-bicyclo [4.3.0] non-active pharmaceutical ingredients (API) of the Gastrointestinal amino tee (Amitiza ®) that is used for the treatment of chronic constipation acid adult non-7-yl) heptane.
[화학식 1] [Chemical Formula 1]
루비프로스톤은 하기 반응식 1에서와 같이, C11의 히드록실 그룹과 C15의 케톤이 반응하여 헤미케탈 고리를 포함하는 바이-사이클릭 형태로 대부분 존재한다. 이러한 형태는 용매에 따라 그 비율이 변화하는데, D2O에서 바이-사이클릭 형태와 모노-사이클릭 형태의 비율은 6:1이고, CDCl3에서 이는 96:4이다(미국 특허 제7,355,064호 참조). Ruby prostone is mostly present in a bi-cyclic form including a hemiketal ring by reacting a hydroxyl group of C < 11 > with a ketone of C < 15 > This ratio varies with the solvent, the ratio of the bi-cyclic form to the mono-cyclic form in D 2 O is 6: 1, and in CDCl 3 it is 96: 4 (see U.S. Patent No. 7,355,064 ).
[반응식 1][Reaction Scheme 1]
미국 특허 제5,284,858호 및 미국 특허 제5,252,605호에는 하기 반응식 2와 같이, 코리 알데히드로부터 ω-체인을 먼저 도입하고 이후 수소화 반응, 환원 반응, 산화 반응, 보호화 그리고 탈보호 반응을 반복하여 최소 10 내지 12단계에 걸쳐 루비프로스톤을 제조하는 방법이 개시되어 있다.U.S. Pat. No. 5,284,858 and U.S. Patent No. 5,252,605 disclose a process for the preparation of a ω-chain by first introducing an ω-chain from a corialdehyde and then hydrogenating, reducing, oxidizing, A method for producing ruby prostone in 12 steps is disclosed.
[반응식 2][Reaction Scheme 2]
미국 특허 제7,812,182호는 코리 락톨로부터 α-체인을 먼저 도입하는 방법에 관한 것으로, 하기 반응식 3과 같이 수소화 반응, 환원 그리고 산화 반응, 보호화 그리고 탈보호 반응을 반복하여 최소 15단계에 걸쳐 루비프로스톤을 제조하는 방법이 개시되어 있다.U.S. Patent No. 7,812,182 relates to a process for the introduction of an alpha -chain from coriolactools first, wherein hydrogenation, reduction, oxidation, protection and deprotection are repeated in at least 15 stages, A method for producing a stone is disclosed.
[반응식 3][Reaction Scheme 3]
상기 루비프로스톤의 공지된 제조 방법은 수소화 반응, 환원 반응, 산화 반응, 보호화 및 탈보호 반응을 반복하는 복잡하고 긴 제조 과정을 거쳐야 하는 문제점이 있었다. The known production method of the rubyprostone has a complicated and long manufacturing process of repeating the hydrogenation reaction, the reduction reaction, the oxidation reaction, the protection and the deprotection reaction.
본 발명자들은 루비프로스톤의 제조에 있어서 상기한 문제점을 해결하고자 예의 연구 검토한 결과, 코리 락톤 디올에 보호기를 선택적으로 도입하여 루비프로스톤을 효율적이고 경제적으로 제조할 수 있음을 알아내고, 본 발명을 완성하게 되었다. The inventors of the present invention have conducted intensive studies in order to solve the above problems in the production of rubyprostone. As a result, they have found that rubyprostone can be efficiently and economically produced by selectively introducing a protecting group into coriolactone diol, .
따라서, 본 발명의 목적은 루비프로스톤을 효율적이고 경제적으로 제조하는 방법을 제공하는 것이다.Accordingly, it is an object of the present invention to provide a method for efficiently and economically producing ruby prostone.
본 발명의 다른 목적은 상기 제조방법에 사용되는 중간체를 제공하는 것이다.Another object of the present invention is to provide an intermediate used in the above-mentioned production method.
본 발명의 일 실시형태는 하기 화학식 1의 루비프로스톤의 제조방법에 관한 것으로, 본 발명의 제조방법은An embodiment of the present invention relates to a process for producing rubyprostone represented by the following formula (1)
(i) 하기 화학식 2의 화합물을 염기의 존재 하에 탈보호 반응시켜 하기 화학식 3의 화합물을 수득하는 단계; (i) deprotecting a compound of formula (2) in the presence of a base to obtain a compound of formula (3);
(ii) 하기 화학식 3의 화합물을 리파아제의 존재 하에 비닐 아세테이트와 반응시켜 1급 히드록실기를 선택적으로 보호하여 하기 화학식 4의 화합물을 수득하는 단계; (ii) reacting a compound of formula (3) with vinyl acetate in the presence of a lipase to selectively protect a primary hydroxyl group to obtain a compound of formula (4);
(iii) 하기 화학식 4의 화합물을 벤질 클로로메틸 에테르와 반응시켜 2급 히드록실기를 보호하여 하기 화학식 5의 화합물을 수득하는 단계;(iii) reacting a compound of formula (4) with benzyl chloromethyl ether to protect the secondary hydroxyl group to obtain a compound of formula (5);
(iv) 하기 화학식 5의 화합물의 케톤을 환원 반응시키고 동시에 1급 히드록실기의 보호기를 탈보호 반응시켜 하기 화학식 6의 화합물을 수득하는 단계;(iv) reducing the ketone of the compound of formula (5) and simultaneously deprotecting the protecting group of the primary hydroxyl group to obtain a compound of formula (6);
(v) 하기 화학식 6의 화합물을 하기 화학식 7의 화합물과 위티그(wittig) 반응시켜 하기 화학식 8의 화합물을 수득하는 단계;(v) subjecting a compound of formula (6) to a Wittig reaction with a compound of formula (7) to obtain a compound of formula (8);
(vi) 하기 화학식 8의 화합물을 벤질 브로마이드와 반응시켜 카복실산기를 보호하여 하기 화학식 9의 화합물을 수득하는 단계;(vi) reacting a compound of formula 8 with benzyl bromide to protect the carboxylic acid group to give a compound of formula 9;
(vii) 하기 화학식 9의 화합물의 1급 및 2급 히드록실기를 산화 반응시켜 하기 화학식 10의 화합물을 수득하는 단계;(vii) oxidizing the primary and secondary hydroxyl groups of the compound of formula (9) to obtain a compound of formula (10);
(viii) 하기 화학식 10의 화합물을 하기 화학식 11의 화합물과 위티그(wittig) 반응시켜 하기 화학식 12의 화합물을 수득하는 단계; 및(viii) subjecting a compound of formula (10) to a Wittig reaction with a compound of formula (11) to obtain a compound of formula (12); And
(ix) 하기 화학식 12의 화합물을 Pd/C에서 수소 하에 수소화 및 탈보호화 반응시키는 단계를 포함한다.(ix) hydrogenating and deprotonating a compound of formula (12) under hydrogen in Pd / C.
[화학식 1] [Chemical Formula 1]
[화학식 2] (2)
[화학식 3] (3)
[화학식 4] [Chemical Formula 4]
[화학식 5] [Chemical Formula 5]
[화학식 6] [Chemical Formula 6]
[화학식 7] (7)
[화학식 8] [Chemical Formula 8]
[화학식 9] [Chemical Formula 9]
[화학식 10] [Chemical formula 10]
[화학식 11] (11)
[화학식 12] [Chemical Formula 12]
상기 식에서,In this formula,
Bz은 벤조일기이고,Bz is a benzoyl group,
Ac는 아세틸기이며,Ac is an acetyl group,
R 및 Bn은 벤질기이다.
R and Bn are benzyl groups.
이하, 본 발명의 제조방법을 하기 반응식 4를 참조로 보다 상세히 설명한다. 하기 반응식 4에 기재된 방법은 대표적으로 사용된 방법을 예시한 것일 뿐 반응시약, 반응조건 등은 경우에 따라 얼마든지 변경될 수 있다.Hereinafter, the production method of the present invention will be described in more detail with reference to Reaction Scheme 4 below. The method described in the following Reaction Scheme 4 exemplifies the representative method, but the reaction reagent, the reaction conditions, and the like may be changed as required.
[반응식 4][Reaction Scheme 4]
제1단계: 화학식 3의 화합물의 합성Step 1: Synthesis of Compound (3)
화학식 3의 화합물은 화학식 2의 화합물을 염기의 존재 하에 탈보호 반응시켜 제조할 수 있다.The compound of formula (3) can be prepared by deprotecting the compound of formula (2) in the presence of a base.
상기 염기로는 일반적인 무기 염기, 예를 들어 수산화나트륨, 수산화칼륨, 수산화리튬과 같은 수산화 알칼리금속 및 탄산나트륨, 탄산칼륨, 탄산수소나트륨, 탄산수소칼륨과 같은 탄산 알칼리금속; 그리고 소디움 메톡사이드, 포타슘 메톡사이드, 소디움 t-부톡사이드, 포타슘 t-부톡사이드 등이 사용될 수 있고, 특히 소디움 메톡사이드(NaOMe)가 적합하다.Examples of the base include general inorganic bases such as alkali metal hydroxides such as sodium hydroxide, potassium hydroxide and lithium hydroxide; alkali metal carbonates such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate and potassium hydrogen carbonate; Sodium methoxide, potassium methoxide, sodium t-butoxide, potassium t-butoxide and the like can be used, and sodium methoxide (NaOMe) is particularly suitable.
반응용매로는 반응에 영향을 주지 않는 극성 용매나 비극성 용매 모두 사용 가능하며, 구체적으로는 테트라히드로푸란, 에테르, 메탄올 등이 사용될 수 있고, 특히 메탄올이 바람직하다.As the reaction solvent, any polar or non-polar solvent which does not affect the reaction can be used. Specifically, tetrahydrofuran, ether, methanol and the like can be used, and methanol is particularly preferable.
반응온도는 실온이 적합하고, 반응시간은 약 1 내지 3시간이 바람직하다.
The reaction temperature is preferably room temperature, and the reaction time is preferably about 1 to 3 hours.
제2단계: 화학식 4의 화합물의 합성Step 2: Synthesis of Compound (4)
화학식 4의 화합물은 화학식 3의 화합물을 리파아제의 존재 하에 비닐 아세테이트와 반응시켜 1급 히드록실기를 선택적으로 보호하여 제조할 수 있다.The compound of formula (4) can be prepared by reacting the compound of formula (3) with vinyl acetate in the presence of lipase to selectively protect the primary hydroxyl group.
상기 리파아제로는 알칼리성 인산가수분해효소(Alkaline Phosphatase: ALPS) 등을 사용할 수 있으나, 이에 제한되는 것은 아니다. As the lipase, alkaline phosphatase (ALPS) or the like may be used, but it is not limited thereto.
반응용매로는 테트라히드로푸란, 에테르, 아세톤 등이 사용될 수 있고, 특히 테트라히드로푸란이 바람직하다.As the reaction solvent, tetrahydrofuran, ether, acetone and the like can be used, and tetrahydrofuran is particularly preferable.
반응온도는 약 30 내지 50 ℃가 적합하고, 반응시간은 약 20 내지 28 시간이 바람직하다.
The reaction temperature is preferably about 30 to 50 DEG C, and the reaction time is preferably about 20 to 28 hours.
제3단계: 화학식 5의 화합물의 합성Step 3: Synthesis of Compound (5)
화학식 5의 화합물은 화학식 4의 화합물을 벤질 클로로메틸 에테르와 반응시켜 2급 히드록실기를 보호하여 제조할 수 있다.The compound of formula (5) can be prepared by reacting the compound of formula (4) with benzyl chloromethyl ether to protect the secondary hydroxyl group.
상기 반응은 염기의 존재 하에 수행될 수 있다. 상기 염기로는 디이소프로필에틸아민, 트리에틸아민 등이 사용될 수 있고, 특히 디이소프로필에틸아민이 적합하다.The reaction may be carried out in the presence of a base. As the base, diisopropylethylamine, triethylamine and the like can be used, and diisopropylethylamine is particularly suitable.
반응용매로는 메틸렌 클로라이드, 클로로포름 등이 사용될 수 있고, 특히 메틸렌 클로라이드가 바람직하다.As the reaction solvent, methylene chloride, chloroform and the like can be used, and methylene chloride is particularly preferable.
반응온도는 실온이 적합하고, 반응시간은 약 25 내지 35시간이 바람직하다.
The reaction temperature is preferably room temperature, and the reaction time is preferably about 25 to 35 hours.
제4단계: 화학식 6의 화합물의 합성Step 4: Synthesis of compound of formula (6)
화학식 6의 화합물은 화학식 5의 화합물의 케톤을 환원 반응시키고 동시에 1급 히드록실기의 보호기를 탈보호 반응시켜 제조할 수 있다.The compound of formula (6) can be prepared by reducing the ketone of the compound of formula (5) and simultaneously deprotecting the protecting group of the primary hydroxyl group.
상기 반응은 디이소부틸알루미늄 하이드라이드(DIBAL)과 같은 환원제의 존재 하에 수행될 수 있다. 과량의 DIBAL을 사용하여 환원 반응과 탈보호 반응을 동시에 진행시킨다.The reaction may be carried out in the presence of a reducing agent such as diisobutyl aluminum hydride (DIBAL). Excess DIBAL is used to conduct reduction and deprotection simultaneously.
반응용매로는 테트라히드로푸란, 에테르, 아세톤 등이 사용될 수 있고, 특히 테트라히드로푸란이 바람직하다.As the reaction solvent, tetrahydrofuran, ether, acetone and the like can be used, and tetrahydrofuran is particularly preferable.
반응온도는 약 -45 내지 -65 ℃가 적합하고, 반응시간은 약 30분 내지 2시간이 바람직하다.
The reaction temperature is preferably about -45 to -65 占 폚, and the reaction time is preferably about 30 minutes to 2 hours.
제5단계: 화학식 8의 화합물의 합성Step 5: Synthesis of Compound of Formula 8
화학식 8의 화합물은 화학식 6의 화합물을 화학식 7의 화합물과 위티그(wittig) 반응시켜 제조할 수 있다.The compound of formula (8) can be prepared by the Wittig reaction of the compound of formula (6) with the compound of formula (7).
상기 반응은 염기의 존재 하에 수행될 수 있다. 상기 염기로는 소디움 메톡사이드, 포타슘 메톡사이드, 소디움 t-부톡사이드, 포타슘 t-부톡사이드 등이 사용될 수 있고, 특히 포타슘 t-부톡사이드가 적합하다.The reaction may be carried out in the presence of a base. As the base, sodium methoxide, potassium methoxide, sodium t-butoxide, potassium t-butoxide and the like can be used, and potassium t-butoxide is particularly suitable.
반응용매로는 테트라히드로푸란, 에테르, 아세톤 등이 사용될 수 있고, 특히 테트라히드로푸란이 바람직하다.As the reaction solvent, tetrahydrofuran, ether, acetone and the like can be used, and tetrahydrofuran is particularly preferable.
반응온도는 실온이 적합하고, 반응시간은 약 1 내지 3 시간이 바람직하다.The reaction temperature is preferably room temperature, and the reaction time is preferably about 1 to 3 hours.
상기 반응을 통해 수득한 화학식 8의 화합물은 별도의 정제과정 없이 바로 다음 반응에 사용될 수 있다.
The compound of the formula 8 obtained through the above reaction can be used for the next reaction without further purification.
제6단계: 화학식 9의 화합물의 합성Step 6: Synthesis of Compound (9)
화학식 9의 화합물은 화학식 8의 화합물을 벤질 브로마이드와 반응시켜 카복실산기를 보호하여 제조할 수 있다. The compound of formula (9) can be prepared by reacting the compound of formula (8) with benzyl bromide to protect the carboxylic acid group.
상기 반응은 염기의 존재 하에 수행될 수 있다. 상기 염기로는 포타슘 카보네이트, 소듐 카보네이트 등이 사용될 수 있고, 특히 포타슘 카보네이트가 적합하다.The reaction may be carried out in the presence of a base. As the base, potassium carbonate, sodium carbonate and the like can be used, and potassium carbonate is particularly suitable.
반응용매로는 테트라히드로푸란, 에테르, 아세톤 등이 사용될 수 있고, 특히 아세톤이 바람직하다.As the reaction solvent, tetrahydrofuran, ether, acetone and the like can be used, and acetone is particularly preferable.
반응온도는 실온이 적합하고, 반응시간은 약 15 내지 23 시간이 바람직하다.
The reaction temperature is preferably room temperature, and the reaction time is preferably about 15 to 23 hours.
제7단계: 화학식 10의 화합물의 합성Step 7: Synthesis of compound of formula (10)
화학식 10의 화합물은 화학식 9의 화합물의 1급 및 2급 히드록실기를 산화 반응시켜 제조할 수 있다. The compound of formula (10) can be prepared by the oxidation reaction of the primary and secondary hydroxyl groups of the compound of formula (9).
상기 반응은 데스-마틴 퍼아이오디난(DMP)과 같은 산화제의 존재 하에 수행될 수 있다.The reaction may be carried out in the presence of an oxidizing agent such as des-martin periodin (DMP).
반응용매로는 메틸렌 클로라이드, 클로로포름 등이 사용될 수 있고, 특히 메틸렌 클로라이드가 바람직하다.As the reaction solvent, methylene chloride, chloroform and the like can be used, and methylene chloride is particularly preferable.
반응온도는 실온이 적합하고, 반응시간은 약 1 내지 3시간이 바람직하다.
The reaction temperature is preferably room temperature, and the reaction time is preferably about 1 to 3 hours.
제8단계: 화학식 12의 화합물의 합성Step 8: Synthesis of compound of formula (12)
화학식 12의 화합물은 화학식 10의 화합물을 화학식 11의 화합물과 위티그(wittig) 반응시켜 제조할 수 있다. The compound of formula (12) can be prepared by subjecting a compound of formula (10) to a wittig reaction with a compound of formula (11).
상기 반응은 염기의 존재 하에 수행될 수 있다. 상기 염기로는 리튬 히드록사이드, 소디움 히드록사이드, 포타슘 히드록사이드 등이 사용될 수 있고, 특히 리튬 히드록사이드가 적합하다.The reaction may be carried out in the presence of a base. As the base, lithium hydroxide, sodium hydroxide, potassium hydroxide and the like can be used, and lithium hydroxide is particularly suitable.
반응용매로는 테트라히드로푸란, 메틸 t-부틸에테르, 물 등이 사용될 수 있고, 특히 메틸 t-부틸에테르, 물 또는 이들의 혼합용매가 바람직하다.As the reaction solvent, tetrahydrofuran, methyl t-butyl ether, water and the like can be used, and particularly methyl t-butyl ether, water or a mixed solvent thereof is preferable.
반응온도는 실온이 적합하고, 반응 시간은 약 45 내지 55 시간이 바람직하다.
The reaction temperature is preferably room temperature, and the reaction time is preferably about 45 to 55 hours.
상기 화학식 11의 화합물은 공지된 방법에 따라 하기 화학식 13의 화합물의 케톤기를 디플루오린화 반응시켜 하기 화학식 14의 화합물을 수득한 후, 하기 화학식 14의 화합물의 에스터기를 위티그(wittig) 반응시켜 제조할 수 있다.The compound of formula (11) can be obtained by subjecting a ketone group of the following formula (13) to a difluorination reaction according to a known method to obtain a compound of the following formula (14) and then subjecting the ester group of the compound of the formula can do.
[화학식 13][Chemical Formula 13]
[화학식 14] [Chemical Formula 14]
제9단계: 루비프로스톤의 합성Step 9: Synthesis of Ruby Prostone
화학식 1의 루비프로스톤은 화학식 12의 화합물을 Pd/C에서 수소 하에 수소화 및 탈보호화 반응시켜 제조할 수 있다.The rubyprostones of formula (I) can be prepared by hydrogenating and deprotecting the compound of formula (12) under hydrogen at Pd / C.
상기 반응은 산의 존재 하에 수행될 수 있다. 상기 산으로는 아세트산, 염산, 황산, 포름산, 인산 등이 사용될 수 있고, 특히 아세트산이 적합하다.The reaction may be carried out in the presence of an acid. As the acid, acetic acid, hydrochloric acid, sulfuric acid, formic acid, phosphoric acid and the like can be used, and acetic acid is particularly suitable.
반응용매로는 이소프로필알코올, 메탄올, 테트라히드로푸란 등이 사용될 수 있고, 특히 이소프로필알코올이 바람직하다.As the reaction solvent, isopropyl alcohol, methanol, tetrahydrofuran and the like can be used, and isopropyl alcohol is particularly preferable.
반응온도는 실온이 적합하고, 반응 시간은 약 20 내지 30 시간이 바람직하다.
The reaction temperature is preferably room temperature, and the reaction time is preferably about 20 to 30 hours.
본 발명의 일 실시형태는 루비프로스톤의 제조 중간체인 하기 화학식 5의 화합물에 관한 것이다.One embodiment of the present invention relates to a compound of formula (5), which is a production intermediate of rubyprostone.
[화학식 5] [Chemical Formula 5]
상기 식에서,In this formula,
Ac는 아세틸기이고,Ac is an acetyl group,
R은 벤질기이다.
R is a benzyl group.
본 발명의 일 실시형태는 상기 화학식 5의 화합물의 제조방법에 관한 것으로, 본 발명의 제조방법은 One embodiment of the present invention relates to a method for producing the compound of Chemical Formula 5,
(i) 하기 화학식 2의 화합물을 염기의 존재 하에 탈보호 반응시켜 하기 화학식 3의 화합물을 수득하는 단계; (i) deprotecting a compound of formula (2) in the presence of a base to obtain a compound of formula (3);
(ii) 하기 화학식 3의 화합물을 리파아제의 존재 하에 비닐 아세테이트와 반응시켜 1급 히드록실기를 선택적으로 보호하여 하기 화학식 4의 화합물을 수득하는 단계; 및(ii) reacting a compound of formula (3) with vinyl acetate in the presence of a lipase to selectively protect a primary hydroxyl group to obtain a compound of formula (4); And
(iii) 하기 화학식 4의 화합물을 벤질 클로로메틸 에테르와 반응시켜 2급 히드록실기를 보호하여 하기 화학식 5의 화합물을 수득하는 단계를 포함한다.(iii) reacting a compound of formula (4) with benzyl chloromethyl ether to protect the secondary hydroxyl group to give a compound of formula (5).
[화학식 2] (2)
[화학식 3] (3)
[화학식 4] [Chemical Formula 4]
상기 식에서,In this formula,
Bz은 벤조일기이고,Bz is a benzoyl group,
Ac는 아세틸기이다.
Ac is an acetyl group.
상기 화학식 5의 화합물의 제조방법에 대한 상세한 설명은 루비프로스톤의 제조방법과 관련하여 상술한 제1단계 내지 제3단계와 동일하므로, 중복을 피하기 위해 구체적인 설명을 생략한다.
The detailed description of the method of preparing the compound of Chemical Formula 5 is the same as the first to third steps described above with respect to the production method of rubyprosthone, so a detailed description will be omitted in order to avoid duplication.
본 발명의 다른 실시형태는 상기 화학식 5의 화합물로부터 상기 화학식 1의 루비프로스톤의 제조방법에 관한 것으로, 본 발명의 다른 실시형태에 따른 제조방법은Another embodiment of the present invention relates to a process for preparing a rubyprostone represented by the general formula (1) from the compound of the general formula (5), and a production process according to another embodiment of the present invention
(iv) 하기 화학식 5의 화합물의 케톤을 환원 반응시키고 동시에 1급 히드록실기의 보호기를 탈보호 반응시켜 하기 화학식 6의 화합물을 수득하는 단계;(iv) reducing the ketone of the compound of formula (5) and simultaneously deprotecting the protecting group of the primary hydroxyl group to obtain a compound of formula (6);
(v) 하기 화학식 6의 화합물을 하기 화학식 7의 화합물과 위티그(wittig) 반응시켜 하기 화학식 8의 화합물을 수득하는 단계;(v) subjecting a compound of formula (6) to a Wittig reaction with a compound of formula (7) to obtain a compound of formula (8);
(vi) 하기 화학식 8의 화합물을 벤질 브로마이드와 반응시켜 카복실산기를 보호하여 하기 화학식 9의 화합물을 수득하는 단계;(vi) reacting a compound of formula 8 with benzyl bromide to protect the carboxylic acid group to give a compound of formula 9;
(vii) 하기 화학식 9의 화합물의 1급 및 2급 히드록실기를 산화 반응시켜 하기 화학식 10의 화합물을 수득하는 단계;(vii) oxidizing the primary and secondary hydroxyl groups of the compound of formula (9) to obtain a compound of formula (10);
(viii) 하기 화학식 10의 화합물을 하기 화학식 11의 화합물과 위티그(wittig) 반응시켜 하기 화학식 12의 화합물을 수득하는 단계; 및(viii) subjecting a compound of formula (10) to a Wittig reaction with a compound of formula (11) to obtain a compound of formula (12); And
(ix) 하기 화학식 12의 화합물을 Pd/C에서 수소 하에 수소화 및 탈보호화 반응시키는 단계를 포함한다.(ix) hydrogenating and deprotonating a compound of formula (12) under hydrogen in Pd / C.
[화학식 5] [Chemical Formula 5]
[화학식 6] [Chemical Formula 6]
[화학식 7] (7)
[화학식 8] [Chemical Formula 8]
[화학식 9] [Chemical Formula 9]
[화학식 10] [Chemical formula 10]
[화학식 11] (11)
[화학식 12] [Chemical Formula 12]
상기 식에서,In this formula,
Ac는 아세틸기이고,Ac is an acetyl group,
R 및 Bn은 벤질기이다.R and Bn are benzyl groups.
본 발명에 따르면, 코리 락톤 디올에 보호기를 선택적으로 도입하여 루비프로스톤을 복잡하고 긴 제조 과정을 거치지 않고, 효율적이고 경제적으로 제조할 수 있다. According to the present invention, it is possible to efficiently and economically produce a ruby prostone by introducing a protecting group selectively into the coriolactone diol without a complicated and long manufacturing process.
이하, 실시예에 의해 본 발명을 보다 구체적으로 설명하고자 한다. 이들 실시예는 오직 본 발명을 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 국한되지 않는다는 것은 당업자에게 있어서 자명하다.
Hereinafter, the present invention will be described in more detail with reference to Examples. It should be apparent to those skilled in the art that these embodiments are for illustrative purpose only and that the scope of the present invention is not limited to these embodiments.
제조예 1: 화학식 14의 화합물의 제조Preparation Example 1: Preparation of the compound of formula (14)
에틸 2-옥소헥사노애이트(13) (148 g)를 메틸렌 클로라이드 (1480 mL)에 희석하여 교반하고 반응액을 0 ℃로 냉각시켰다. 디에틸아미노설퍼 트리플루오라이드 (148 mL)을 천천히 적가하고 반응액을 실온으로 승온하여 4시간 동안 교반하였다. 반응의 진행을 박막 크로마토그래피 (헥산 : 에틸아세테이트 = 10 : 1)에 의해 관측하였다. 반응 완료 후, 포화 중탄산나트륨 수용액 (1000 mL)을 천천히 넣었다. 이후 물층을 메틸렌 클로라이드 (1000 mL)으로 추출하고 유기층을 분리하여 무수황산나트륨 중에서 건조하였다. 무수황산나트륨 여과 후 여액을 진공 중에 농축하여 혼합물을 수득하였고, 실리카겔을 사용한 칼럼 크로마토그래피 (헥산 : 에틸아세테이트 = 30 : 1)로 정제하여 순수한 에틸 2,2-디플루오로헥사노애이트(14) (151g, 90%)를 수득하였다.
Ethyl 2-oxohexanoate (13) (148 g) was diluted with methylene chloride (1480 mL) and stirred, and the reaction solution was cooled to 0 占 폚. Diethylaminosulfur trifluoride (148 mL) was slowly added dropwise and the reaction solution was warmed to room temperature and stirred for 4 hours. The progress of the reaction was observed by thin layer chromatography (hexane: ethyl acetate = 10: 1). After completion of the reaction, a saturated aqueous sodium bicarbonate solution (1000 mL) was slowly added. The aqueous layer was then extracted with methylene chloride (1000 mL), and the organic layer was separated and dried in anhydrous sodium sulfate. After filtration of anhydrous sodium sulfate, the filtrate was concentrated in vacuo to give a mixture which was purified by column chromatography using silica gel (hexane: ethyl acetate = 30: 1) to give pure ethyl 2,2-difluorohexanoate (14) (151 g, 90%).
제조예 2: 화학식 11의 화합물의 제조Preparation Example 2: Preparation of the compound of formula (11)
디메틸 메틸포스포네이트 (215 mL)를 THF (1450 mL)에 희석하여 교반하고 반응액을 -78 ℃로 냉각시켰다. n-BuLi (804 mL)을 적가하여 2시간 동안 교반하고 에틸 2,2-디플루오로헥사노애이트(14) (145 g)를 적가하였다. 1시간 동안 교반한 후, 0 ℃로 승온하여 1시간 동안 교반하였다. 반응 진행을 박막 크로마토그래피 (헥산 : 에틸아세테이트 = 1 : 1)에 의해 관측하였다. 반응 완료 후, 펜탄 (1000 mL)을 가하고 2M-황산 용액으로 pH 6으로 조절하였다. 물층은 분리하여 펜탄으로 재추출 하고 유기층을 합하여 무수황산나트륨 중에서 건조하였다. 무수황산나트륨 여과 후 여액을 진공 중에 농축하여 혼합물을 수득하였고, 실리카겔을 사용한 칼럼 크로마토그래피 (헥산 : 에틸아세테이트 = 1 : 1)로 정제하여 순수한 디메틸 3,3-디플루오로-2-옥소헵틸포스포네이트(11) (161 g, 78%)을 수득하였다.
Dimethyl methylphosphonate (215 mL) was diluted in THF (1450 mL) and stirred, and the reaction solution was cooled to -78 ° C. n-BuLi (804 mL) was added dropwise and stirred for 2 hours, and ethyl 2,2-difluorohexanoate (14) (145 g) was added dropwise. After stirring for 1 hour, the temperature was raised to 0 占 폚 and stirred for 1 hour. The progress of the reaction was monitored by thin layer chromatography (hexane: ethyl acetate = 1: 1). After completion of the reaction, pentane (1000 mL) was added and the pH was adjusted to 6 with 2M-sulfuric acid solution. The water layer was separated, re-extracted with pentane, and the organic layers were combined and dried in anhydrous sodium sulfate. After filtration of anhydrous sodium sulfate, the filtrate was concentrated in vacuo to give a mixture which was purified by column chromatography using silica gel (hexane: ethyl acetate = 1: 1) to give pure dimethyl 3,3-difluoro-2-oxoheptylphosphate Nat 11 (161 g, 78%) was obtained.
실시예 1: 화학식 3의 화합물의 제조Example 1: Preparation of the compound of formula (III)
코리락톤벤조에이트(2) (100 g)를 메탄올 (500 mL)에 현탁시켰다. 그런 다음, 소디움 메톡사이드 (2 g)를 메탄올 (10 mL)에 녹여 20 ℃ 내지 25 ℃의 온도에서 적가하고 실온에서 2시간 동안 교반한 후, 반응의 진행을 박층 크로마토그래피 (헥산 : 에틸아세테이트 = 1 : 5)에 의해 관측하였다. 반응 완료 후, 1,4-디옥산에 희석한 4M-염산용액 (8 mL)을 가하여 pH를 3 내지 4로 맞추었다. 10분 동안 교반하고 농축한 후, 메틸 t-부틸에테르 (400 mL)를 넣어 현탁한 후 농축하였다. 그런 다음, 메틸 t-부틸에테르 (1000 mL)를 넣고 실온에서 1시간 동안 교반한 후, 고체를 여과하고 메틸 t-부틸에테르로 세척하였다. 고체를 진공 건조하여 흰색 고체의 (3aR,4S,5R,6aS)-5-히드록시-4-(히드록시메틸)헥사히드로-2H-사이클로펜타[b]푸란-2-원(3) (59 g, 95%)을 수득하였다.Coriolactone benzoate (2) (100 g) was suspended in methanol (500 mL). Then, sodium methoxide (2 g) was dissolved in methanol (10 mL), and the mixture was added dropwise at a temperature of 20 ° C to 25 ° C and stirred at room temperature for 2 hours. The progress of the reaction was confirmed by thin layer chromatography (hexane: ethyl acetate = 1: 5). After completion of the reaction, 4M-hydrochloric acid solution (8 mL) diluted in 1,4-dioxane was added to adjust the pH to 3 to 4. After stirring for 10 minutes and concentration, the mixture was suspended in methyl t-butyl ether (400 mL) and then concentrated. Then, after adding methyl t-butyl ether (1000 mL) and stirring at room temperature for 1 hour, the solid was filtered and washed with methyl t-butyl ether. Dry the solid in vacuo to a white solid (3a R, 4 S, 5 R, 6a S) -5- hydroxy-4- (hydroxymethyl) -2-hexahydro-H - cyclopenta [b] furan-2-circle (3) (59 g, 95%).
1H NMR (300 MHz, CDCl3) : δ 4.95 (1H, ddd, J = 6.9, 4.8, 2.4 Hz), 4.04 (1H, q, J = 5.1 Hz), 3.49 (2H, m), 2.84 (1H, q, J = 7.8 Hz), 2.72 (1H, m), 2.49 (1H, dd, J = 15.6, 2.4 Hz), 2.28 (1H, m), 1.91 (2H, m).
1 H NMR (300 MHz, CDCl 3): δ 4.95 (1H, ddd, J = 6.9, 4.8, 2.4 Hz), 4.04 (1H, q, J = 5.1 Hz), 3.49 (2H, m), 2.84 (1H , q, J = 7.8 Hz), 2.72 (1H, m), 2.49 (1H, dd, J = 15.6, 2.4 Hz), 2.28 (1H, m), 1.91 (2H, m).
실시예 2: 화학식 4의 화합물의 제조Example 2: Preparation of the compound of formula (IV)
(3aR,4S,5R,6aS)-5-히드록시-4-(히드록시메틸)헥사히드로-2H-사이클로펜타[b]푸란-2-원(3) (59 g)에 테트라히드로푸란 (1719 mL)을 넣어 현탁시켰다. 비닐 아세테이트 (31.7 mL)를 가하고 ALPS (34.4 g)를 넣은 후, 40 ℃에서 24시간 동안 교반하면서 반응의 진행을 박층 크로마토그래피 (헥산 : 에틸아세테이트 = 1 : 5)에 의해 관측하였다. 반응 완료 후, 셀라이트 패드를 통해 여과하고 진공 중에 농축하였다. 혼합물을 칼럼 크로마토그래피 (헥산 : 에틸아세테이트 = 1 : 5)를 통해 정제하여 순수한 생성물 ((3aR,4S,5R,6aS)-5-히드록시-2-옥소헥사히드로-2H-사이클로펜타[b]푸란-4-일)메틸 아세테이트(4) (66.3 g, 90%)를 수득하였다.The cyclopenta [b] furan-2 source (3) (59 g) - (3a R, 4 S, 5 R, 6a S) -5- hydroxy-4- (hydroxymethyl) -2-hexahydro-H And suspended in tetrahydrofuran (1719 mL). Vinyl acetate (31.7 mL) was added, and ALPS (34.4 g) was added, and the progress of the reaction was observed by thin layer chromatography (hexane: ethyl acetate = 1: 5) while stirring at 40 ° C for 24 hours. After completion of the reaction, the mixture was filtered through a pad of celite and concentrated in vacuo. The mixture was purified by column chromatography (hexane: ethyl acetate = 1: 5) to give the pure product from ((3a R, 4 S, 5 R, 6a S) -5- hydroxy-2-oxo-hexahydro--2 H - Cyclopenta [ b ] furan-4-yl) methyl acetate (4) (66.3 g, 90%).
1H NMR (300 MHz, CDCl3) : δ 4.95 (1H, ddd, J = 6.9, 4.2, 2.7 Hz), 4.08 (3H, m), 2.82 (1H, q, J = 7.8 Hz), 2.66 (1H, m), 2.60 (1H, dd, J = 12.9, 7.2 Hz), 2.39 (1H, m), 2.10 (6H, m).
1 H NMR (300 MHz, CDCl 3): δ 4.95 (1H, ddd, J = 6.9, 4.2, 2.7 Hz), 4.08 (3H, m), 2.82 (1H, q, J = 7.8 Hz), 2.66 (1H m), 2.60 (1H, dd, J = 12.9, 7.2 Hz), 2.39 (1H, m), 2.10 (6H, m).
실시예 3: 화학식 5의 화합물의 제조Example 3: Preparation of the compound of formula (5)
((3aR,4S,5R,6aS)-5-히드록시-2-옥소헥사히드로-2H-사이클로펜타[b]푸란-4-일)메틸 아세테이트(4) (66.3 g)를 메틸렌 클로라이드 (773.7 mL)에 녹여 교반하고 디이소프로필에틸아민 (162 mL)을 가한 후 반응액을 0℃로 냉각시켰다. 벤질 클로로메틸 에테르 (119.56 mL)를 적가하고 실온으로 승온하여 30시간 동안 교반하였다. 반응의 진행을 박층 크로마토그래피 (헥산 : 에틸아세테이트 = 1 : 3)에 의해 관측하였다. 반응 완료 후, 염화 암모늄의 포화용액을 넣고 교반한 다음, 유기층을 분리하여 무수황산나트륨 상에서 건조시키고 여과하였다. 여액을 진공 중에 증발시켜 점성액체를 수득하였다. 혼합물을 칼럼 크로마토그래피 (헥산 : 에틸아세테이트 = 1 : 5)를 통해 정제하여 순수한 생성물 ((3aR,4S,5R,6aS)-5-(벤질옥시메톡시)-2-옥소헥사히드로-2H-사이클로펜타[b]푸란-4-일)메틸 아세테이트(5) (96.2 g, 90%)을 수득하였다.The - (cyclopenta [b] furan-4-one (3a R, 4 S, 5 R, 6a S) -5- hydroxy-2-oxo-hexahydro-H -2) methyl acetate (4) (66.3 g) The reaction mixture was dissolved in methylene chloride (773.7 mL) and stirred. Diisopropylethylamine (162 mL) was added thereto, and the reaction solution was cooled to 0 占 폚. Benzyl chloromethyl ether (119.56 mL) was added dropwise, the temperature was raised to room temperature, and the mixture was stirred for 30 hours. The progress of the reaction was observed by thin layer chromatography (hexane: ethyl acetate = 1: 3). After completion of the reaction, a saturated solution of ammonium chloride was added and stirred, and then the organic layer was separated, dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated in vacuo to give a viscous liquid. The mixture was purified by column chromatography (hexane: ethyl acetate = 1: 5) to give the pure product from ((3a R, 4 S, 5 R, 6a S) -5- ( Benzyloxy-methoxy) -2-oxo-hexahydro- -2 H - cyclopenta [b] furan-4-yl) methyl acetate (5) (96.2 g, yield 90%).
1H NMR (300 MHz, CDCl3) : δ 7.33 (5H, m), 4.97 (1H, ddd, J = 6.9, 4.5, 2.4 Hz), 4.77 (2H, d, J = 7.2 Hz), 4.59 (2H, d, J = 5.4 Hz), 4.03 (4H, m), 2.83 (1H, q, J = 7.8 Hz), 2.67 (1H, m), 2.55 (1H, dd, J = 15, 2.7 Hz), 2.26 (3H, m), 2.05 (3H, s, H9).
1 H NMR (300 MHz, CDCl 3): δ 7.33 (5H, m), 4.97 (1H, ddd, J = 6.9, 4.5, 2.4 Hz), 4.77 (2H, d, J = 7.2 Hz), 4.59 (2H , d, J = 5.4 Hz) , 4.03 (4H, m), 2.83 (1H, q, J = 7.8 Hz), 2.67 (1H, m), 2.55 (1H, dd, J = 15, 2.7 Hz), 2.26 (3H, m), 2.05 (3H, s, H9).
실시예 4: 화학식 6의 화합물의 제조Example 4: Preparation of the compound of formula (VI)
((3aR,4S,5R,6aS)-5-(벤질옥시메톡시)-2-옥소헥사히드로-2H-사이클로펜타[b]푸란-4-일)메틸 아세테이트(5) (96.2 g)를 테트라히드로푸란 (1439 mL)에 희석하고 -50 ℃ 내지 -65 ℃로 냉각시켰다. 디이소부틸알루미늄 하이드라이드 (863.4 mL)를 천천히 적가하고 -50 ℃ 내지 -65 ℃로 유지하며 교반하였다. 반응의 진행을 박층 크로마토그래피 (헥산 : 에틸아세테이트 = 1 : 5)에 의해 관측하였다. 1시간 동안 교반 후 반응 완료 하고 메탄올 (75.78 mL)로 켄칭하였다. 이후 실온으로 승온하고 포화 포타슘 소듐 타르트레이트 (PST) 용액 (962 mL)과 디에틸에테르 (1000 mL)를 넣고 1시간 동안 교반하였다. 그런 다음, 유기층을 분리하여 무수황산나트륨 중에서 건조시키고 여과하여 진공 중에 증발시켜 점성액체를 수득하였다. 혼합물을 칼럼 크로마토그래피 (헥산 : 에틸아세테이트 = 1 : 5)를 통해 정제하여 순수한 생성물 (3aR,4S,5R,6aS)-5-(벤질옥시메톡시)-4-(히드록시메틸)헥사히드로-2H-사이클로펜타[b]푸란-2-올(6) (67.7 g, 80%)을 수득하였다. ((3a R, 4 S, 5 R, 6a S) -5- ( Benzyloxy-methoxy) -2-oxo-hexahydro--2 H - cyclopenta [b] furan-4-yl) methyl acetate (5) ( 96.2 g) was diluted in tetrahydrofuran (1439 mL) and cooled to -50 < 0 > C to -65 < 0 > C. Diisobutyl aluminum hydride (863.4 mL) was slowly added dropwise, and the mixture was kept at -50 ° C to -65 ° C and stirred. The progress of the reaction was observed by thin layer chromatography (hexane: ethyl acetate = 1: 5). After stirring for 1 hour, the reaction was complete and quenched with methanol (75.78 mL). Then, the temperature was raised to room temperature, saturated potassium sodium tartrate (PST) solution (962 mL) and diethyl ether (1000 mL) were added and stirred for 1 hour. The organic layer was then separated, dried in anhydrous sodium sulfate, filtered and evaporated in vacuo to give a viscous liquid. Column and the mixture purified by chromatography (hexane: ethyl acetate = 1: 5) to give the pure product (3a R, 4 S, 5 R, 6a S) through 5- (Benzyloxy-methoxy) -4- (hydroxymethyl ) Hexahydro- 2H -cyclopenta [ b ] furan-2-ol (6) (67.7 g, 80%).
1H NMR (300 MHz, CDCl3) :δ 7.33 (5H, m), 5.58 (1H, m), 4.84 (2H, d, J = 3.3), 4.60 (2H, d, J = 5.7), 4.06 (1H, m), 3.62 (2H, m), 2.11 (7H, m).
1 H NMR (300 MHz, CDCl 3): δ 7.33 (5H, m), 5.58 (1H, m), 4.84 (2H, d, J = 3.3), 4.60 (2H, d, J = 5.7), 4.06 ( 1H, m), 3.62 (2H, m), 2.11 (7H, m).
실시예 5: 화학식 8의 화합물의 제조Example 5: Preparation of compound of formula 8
(4-카르복시부틸)트리페닐포스포늄 브로마이드(7) (249.42 g)를 테트라히드로푸란 (1355 mL)에 현탁시키고 반응액을 0 ℃로 냉각시켰다. 그런 다음, 포타슘 t-부톡시드 (129.18 g)를 넣고 실온으로 승온하여 교반하였다. (3aR,4S,5R,6aS)-5-(벤질옥시메톡시)-4-(히드록시메틸)헥사히드로-2H-사이클로펜타[b]푸란-2-올(6) (67.7 g)을 테트라히드로푸란 (680 mL)에 희석하여 적가하고 실온에서 2시간 동안 교반하였다. 반응의 진행을 박층 크로마토그래피 (에틸아세테이트 : 아세톤 : 메탄올 = 10 : 1 : 1)에 의해 관측하였다. 반응 완료 후 반응물을 10 ℃로 냉각시키고 얼음물 (670 mL)을 가하였다. 디에틸에테르 (1000 mL)로 물층을 세척하여 불순물을 제거하고, 물층은 분리하여 1N-염산으로 pH 4 내지 pH 5로 조절하였다. 에틸아세테이트 (1000 mL)로 추출하고 유기층을 분리하여 무수황산나트륨 중에서 건조시켰다. 그런 다음, 여과하고 진공 중에 농축하여 (Z)-7-((1R,2S,3R,5S)-3-(벤질옥시메톡시)-5-히드록시-2-(히드록시메틸)사이클로펜틸)헵트-5-에논산(8)을 수득하였다. 수득한 (Z)-7-((1R,2S,3R,5S)-3-(벤질옥시메톡시)-5-히드록시-2-(히드록시메틸)사이클로펜틸)헵트-5-에논산(8)은 별도의 정제과정 없이 바로 다음 반응에 사용하였다.
(4-carboxybutyl) triphenylphosphonium bromide (7) (249.42 g) was suspended in tetrahydrofuran (1355 mL) and the reaction solution was cooled to 0 占 폚. Then, potassium t-butoxide (129.18 g) was added and the mixture was heated to room temperature and stirred. (3a R, 4 S, 5 R, 6a S) -5- ( Benzyloxy-methoxy) -4- (hydroxymethyl) -2-hexahydro-H - cyclopenta [b] furan-2-ol (6) ( 67.7 g) was diluted with tetrahydrofuran (680 mL), and the mixture was stirred at room temperature for 2 hours. The progress of the reaction was observed by thin layer chromatography (ethyl acetate: acetone: methanol = 10: 1: 1). After completion of the reaction, the reaction was cooled to 10 ° C and ice water (670 mL) was added. The water layer was washed with diethyl ether (1000 mL) to remove impurities and the water layer was separated and adjusted to pH 4 to pH 5 with 1N hydrochloric acid. Extracted with ethyl acetate (1000 mL) and the organic layer was separated and dried in anhydrous sodium sulfate. It is then filtered and concentrated in vacuo to afford ( Z ) -7 - (( 1R , 2S , 3R , 5S ) -3- (benzyloxymethoxy) -5- ) Cyclopentyl) hept-5-enone acid (8). The obtained (Z) -7 - ((1 R, 2 S, 3 R, 5 S) -3- ( benzyloxycarbonyl-methoxy) -5-hydroxy-2- (hydroxymethyl) cyclopentyl) hept -5 -Nonanoic acid (8) was used in the next reaction without further purification.
실시예 6: 화학식 9의 화합물의 제조Example 6: Preparation of the compound of formula (9)
(Z)-7-((1R,2S,3R,5S)-3-(벤질옥시메톡시)-5-히드록시-2-(히드록시메틸)사이클로펜틸)헵트-5-에논산(8) (87.14 g)을 아세톤 (2302 mL)에 녹여 교반하였다. 포타슘 카보네이트 (63.64 g)를 넣고 벤질 브로마이드 (54.77 mL)를 가하여 실온에서 18시간 동안 교반하였다. 반응의 진행을 박막 크로마토그래피 (헥산 : 에틸아세테이트 = 1 : 1)에 의해 관측하였다. 반응 완료 후 셀라이트 패드를 통해 여과하고 진공 중에 농축하여 점성액체를 수득하였다. 혼합물을 칼럼 크로마토그래피 (헥산 : 에틸아세테이트 = 1 : 1)를 통해 정제하여 순수한 생성물 (Z)-벤질 7-((1R,2S,3R,5S)-3-(벤질옥시메톡시)-5-히드록시-2-(히드록시메틸)사이클로펜틸)헵트-5-에노애이트(9) (86.3 g, 80%)를 수득하였다. (Z) -7 - a ((1 R, 2 S, 3 R, 5 S) -3- ( benzyloxycarbonyl-methoxy) -5-hydroxy-2- (hydroxymethyl) cyclopentyl) hept-5 N-Acid 8 (87.14 g) was dissolved in acetone (2302 mL) and stirred. Potassium carbonate (63.64 g) was added, benzyl bromide (54.77 mL) was added, and the mixture was stirred at room temperature for 18 hours. The progress of the reaction was observed by thin layer chromatography (hexane: ethyl acetate = 1: 1). After completion of the reaction, the mixture was filtered through a celite pad and concentrated in vacuo to obtain a viscous liquid. The mixture was purified by column chromatography (hexane: ethyl acetate = 1: 1) to give the pure product ( Z ) -benzyl 7 - (( 1R , 2S , 3R , 5S ) -3- (benzyloxymethoxy ) -5-hydroxy-2- (hydroxymethyl) cyclopentyl) hept-5-enoate (9) (86.3 g, 80%).
1H NMR (700 MHz, CDCl3) :δ 7.35 (10H, m), 5.47 (1H, m), 5.39 (1H, m), 5.10 (2H, s), 4.80 (2H, dd, J = 20.8, 7.0 Hz), 4.62 (2H, dd, J = 21.1, 11.7 Hz), 4.20 (1H, m), 4.12 (1H, m), 3.74 (1H, m), 3.46 (1H, m), 2.35 (3H, m), 2.21 (1H, m), 2.13 (2H, m), 2.02 (1H, m), 1.92 (2H, m), 1.72 (2H, m), 1.49 (1H, m).
1 H NMR (700 MHz, CDCl 3): δ 7.35 (10H, m), 5.47 (1H, m), 5.39 (1H, m), 5.10 (2H, s), 4.80 (2H, dd, J = 20.8, M), 3.46 (1H, m), 2.35 (3H, m), 4.62 (2H, d, J = m), 2.21 (1H, m), 2.13 (2H, m), 2.02 (1H, m), 1.92 (2H, m), 1.72
실시예 7: 화학식 10의 화합물의 제조Example 7: Preparation of the compound of formula (10)
(Z)-벤질 7-((1R,2S,3R,5S)-3-(벤질옥시메톡시)-5-히드록시-2-(히드록시메틸)사이클로펜틸)헵트-5-에노애이트(9) (86.3 g)를 메틸렌 클로라이드 (863.10 mL)에 희석하고 반응액을 0 ℃로 냉각시켰다. 데스-마틴 퍼아이오디난 (234.3 g)을 넣고 10분 동안 교반 후 반응액을 실온으로 승온하여 2시간 동안 교반하였다. 반응 진행을 박막 크로마토그래피 (헥산 : 에틸아세테이트 = 2 : 1)에 의해 관측하였다. 반응 완료 후, 10% 티오황산나트륨 (2500 mL)과 포화 중탄산나트륨 (2500 mL)으로 켄칭하였다. 유기층을 분리하고 무수황산나트륨 중에서 건조하여 여과 후 진공 중에 농축하였다. 혼합물을 칼럼 크로마토그래피(헥산 : 에틸아세테이트 = 5 : 1)를 통해 정제하여 순수한 생성물 (Z)-벤질 7-((1R,2R,3R)-3-(벤질옥시메톡시)-2-포밀-5-옥소사이클로펜틸)헵트-5-에노애이트(10) (66.25 g, 80%)를 수득하였다. (Z) - benzyl-7 - ((1 R, 2 S, 3 R, 5 S) -3- ( benzyloxycarbonyl-methoxy) -5-hydroxy-2- (hydroxymethyl) cyclopentyl) hept-5 Enoate (9) (86.3 g) was diluted in methylene chloride (863.10 mL) and the reaction was cooled to 0 < 0 > C. Death-Martin Puri Iodine (234.3 g) was added and the mixture was stirred for 10 minutes. Then, the reaction solution was warmed to room temperature and stirred for 2 hours. The progress of the reaction was observed by thin layer chromatography (hexane: ethyl acetate = 2: 1). After completion of the reaction, the reaction mixture was quenched with 10% sodium thiosulfate (2500 mL) and saturated sodium bicarbonate (2500 mL). The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The mixture was purified by column chromatography (hexane: ethyl acetate = 5: 1) to give the pure product ( Z ) -benzyl 7 - (( 1R , 2R , 3R ) -3- (benzyloxymethoxy) -Formyl-5-oxocyclopentyl) hept-5-enoate (10) (66.25 g, 80%).
1H NMR (700MHz, CDCl3) :δ 9.79 (1H, s), 7.31 (10H, m), 5.47 (1H, m), 5.27 (1H, m), 5.11 (2H, s), 4.78 (2H, dd, J = 13.4, 7.1 Hz), 4.58 (2H, s), 4.52 (1H, dd, J = 14.9, 7.5 Hz), 2.99 (1H, m), 2.78 (1H, m), 2.56 (1H, m), 2.45 (1H, m), 2.33 (4H, m), 2.06 (2H, m), 1.70 (2H, m).
1 H NMR (700MHz, CDCl 3 ): δ 9.79 (1H, s), 7.31 (10H, m), 5.47 (1H, m), 5.27 (1H, m), 5.11 (2H, s), 4.78 (2H, dd, J = 13.4, 7.1 Hz ), 4.58 (2H, s), 4.52 (1H, dd, J = 14.9, 7.5 Hz), 2.99 (1H, m), 2.78 (1H, m), 2.56 (1H, m ), 2.45 (1H, m), 2.33 (4H, m), 2.06 (2H, m), 1.70 (2H, m).
실시예 8: 화학식 12의 화합물의 제조Example 8: Preparation of the compound of formula (12)
디메틸 3,3-디플루오로-2-옥소헵틸포스포네이트(11) (73.63 g)을 메틸 t-부틸에테르 (187 mL)에 희석하고 리튬 히드록사이드 (8.98 g)를 넣은 후 실온에서 4시간 동안 교반하였다. 그런 다음, (Z)-벤질 7-((1R,2R,3R)-3-(벤질옥시메톡시)-2-포밀-5-옥소사이클로펜틸)헵트-5-에노애이트(10) (66.25 g)를 메틸 t-부틸에테르 (800 mL)에 희석하여 적가하고, 물 (59.6 mL)을 가한 후 실온에서 48시간 동안 교반하였다. 반응 진행은 박막 크로마토그래피 (헥산 : 에틸아세테이트 = 3 : 1)에 의해 관측하였다. 반응 완료 후, 포화 염화암모늄 수용액을 넣어 교반하고 유기층을 분리하여 무수황산나트륨 중에서 건조하여 여과하였다. 여액을 진공 중에 농축하여 혼합물을 수득하였고, 칼럼 크로마토그래피 (헥산 : 에틸아세테이트 = 5 : 1)로 정제하여 순수한 생성물 (Z)-벤질 7-((1R,2R,3R)-3-(벤질옥시메톡시)-2-((E)-4,4-디플루오로-3-옥소옥트-1-에닐)-5-옥소사이클로펜틸)헵트-5-에노애이트(12) (55.3 g, 65%)을 수득하였다.(73.63 g) of dimethyl 3,3-difluoro-2-oxoheptylphosphonate (11) was diluted with methyl t-butyl ether (187 mL), lithium hydroxide (8.98 g) Lt; / RTI > Then, (Z) - benzyl-7 - ((1 R, 2 R, 3 R) -3- ( Benzyloxy-methoxy) -2-formyl-5-oxo-cyclopentyl) hept-5-enoic aeyi bit (10 ) (66.25 g) was diluted with methyl t-butyl ether (800 mL), added dropwise with water (59.6 mL), and stirred at room temperature for 48 hours. The progress of the reaction was observed by thin layer chromatography (hexane: ethyl acetate = 3: 1). After completion of the reaction, a saturated aqueous solution of ammonium chloride was added and stirred, and the organic layer was separated, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give a mixture in vacuo, column chromatography (hexane: ethyl acetate = 5: 1) to give pure product (Z) - benzyl-7 - ((1 R, 2 R, 3 R) -3- (Benzyloxymethoxy) -2 - (( E ) -4,4-difluoro-3-oxooct-1-enyl) -5-oxocyclopentyl) hept-5-enoate g, 65%).
1H NMR (700MHz, CDCl3) :δ 7.32 (10H, m), 7.12 (1H, dd, J = 15.5, 8.6 Hz), 6.67 (1H, dd, J = 15.5, 0.7 Hz), 5.44 (1H, m), 5.26 (1H, m), 5.10 (2H, s), 4.75 (2H, dd, J = 14.9, 7.1 Hz), 4.54 (2H, dd, J = 14.6, 11.7 Hz), 4.18 (1H, m), 2.83 (2H, m), 2.35 (4H, m), 2.24 (2H, m), 2.01 (4H, m), 1.69 (2H, m), 1.39 (4H, m), 0.89 (3H, t, J = 7.2 Hz).
1 H NMR (700MHz, CDCl 3 ): δ 7.32 (10H, m), 7.12 (1H, dd, J = 15.5, 8.6 Hz), 6.67 (1H, dd, J = 15.5, 0.7 Hz), 5.44 (1H, m), 5.26 (1H, m ), 5.10 (2H, s), 4.75 (2H, dd, J = 14.9, 7.1 Hz), 4.54 (2H, dd, J = 14.6, 11.7 Hz), 4.18 (1H, m ), 2.83 (2H, m), 2.35 (4H, m), 2.24 (2H, m), 2.01 (4H, m), 1.69 J = 7.2 Hz).
실시예 9: 루비프로스톤의 제조Example 9: Preparation of rubyprostone
(Z)-벤질 7-((1R,2R,3R)-3-(벤질옥시메톡시)-2-((E)-4,4-디플루오로-3-옥소옥트-1-에닐)-5-옥소사이클로펜틸)헵트-5-에노애이트(12) (55.3 g)를 이소프로필알코올 (300 mL)에 희석하여 교반하였다. 10% Pd/C (11.06 g)를 이소프로필알코올 (806 mL)에 희석하여 넣고 아세트산 (0.53 mL)을 가하였다. 반응 혼합물을 24시간 동안 수소 하에 실온에서 교반하였다. 반응의 진행을 박막 크로마토그래피 (헥산 : 에틸아세테이트 = 1 : 1)에 의해 관측하였다. 반응 완료 후, 셀라이트 패드를 통하여 여과하고 여액을 진공 중에 농축하여 혼합물을 수득하였다. 혼합물을 칼럼 크로마토그래피 (메틸렌 클로라이드 : 메틸 t-부틸에테르 = 2 : 1)로 정제하여 루비프로스톤(1) (32 g, 90%)을 수득하였다.( Z ) -benzyl 7 - (( 1R , 2R , 3R ) -3- (benzyloxymethoxy) -2 - (( E ) -4,4-difluoro- Enyl) -5-oxocyclopentyl) hept-5-enoate (12) (55.3 g) was diluted with isopropyl alcohol (300 mL) and stirred. 10% Pd / C (11.06 g) was diluted in isopropyl alcohol (806 mL) and acetic acid (0.53 mL) was added. The reaction mixture was stirred at room temperature under hydrogen for 24 hours. The progress of the reaction was observed by thin layer chromatography (hexane: ethyl acetate = 1: 1). After completion of the reaction, the mixture was filtered through a pad of celite and the filtrate was concentrated in vacuo to give a mixture. The mixture was purified by column chromatography (methylene chloride: methyl t-butyl ether = 2: 1) to obtain rubyprostone (1) (32 g, 90%).
점성 액체의 루비프로스톤을 에틸아세테이트 (2 볼륨)에 녹이고 헥산 (10 볼륨)을 적가하며 강하게 교반하였다. 희뿌연 용액상태의 반응액을 5 ℃ 내지 10 ℃로 냉각시킨 후 교반하여 고순도의 루비프로스톤을 수득하였다.The viscous liquid rubyprostone was dissolved in ethyl acetate (2 volumes) and vigorously stirred with hexane (10 volumes) added dropwise. The reaction solution in the dilute solution state was cooled to 5 캜 to 10 캜 and stirred to obtain a high-purity rubyprosthone.
1H NMR (700MHz, CDCl3) :δ 4.18 (1H, ddd, J = 11.4, 10.0, 7.2 Hz), 2.57 (1H, dd, J = 17.6, 7.2 Hz), 2.34 (2H, t, J = 7.4 Hz), 2.25 (1H, dd, J = 17.7, 11.6 Hz), 1.96 (4H, m), 1.81 (3H, m), 1.58 (7H, m), 1.36 (8H, m), 0.93 (3H, t, J = 7.3 Hz). 1 H NMR (700MHz, CDCl 3 ): δ 4.18 (1H, ddd, J = 11.4, 10.0, 7.2 Hz), 2.57 (1H, dd, J = 17.6, 7.2 Hz), 2.34 (2H, t, J = 7.4 Hz), 2.25 (1H, dd , J = 17.7, 11.6 Hz), 1.96 (4H, m), 1.81 (3H, m), 1.58 (7H, m), 1.36 (8H, m), 0.93 (3H, t , J = 7.3 Hz).
Claims (18)
(ii) 하기 화학식 3의 화합물을 리파아제의 존재 하에 비닐 아세테이트와 반응시켜 1급 히드록실기를 선택적으로 보호하여 하기 화학식 4의 화합물을 수득하는 단계;
(iii) 하기 화학식 4의 화합물을 벤질 클로로메틸 에테르와 반응시켜 2급 히드록실기를 보호하여 하기 화학식 5의 화합물을 수득하는 단계;
(iv) 하기 화학식 5의 화합물의 케톤을 환원 반응시키고 동시에 1급 히드록실기의 보호기를 탈보호 반응시켜 하기 화학식 6의 화합물을 수득하는 단계;
(v) 하기 화학식 6의 화합물을 하기 화학식 7의 화합물과 위티그(wittig) 반응시켜 하기 화학식 8의 화합물을 수득하는 단계;
(vi) 하기 화학식 8의 화합물을 벤질 브로마이드와 반응시켜 카복실산기를 보호하여 하기 화학식 9의 화합물을 수득하는 단계;
(vii) 하기 화학식 9의 화합물의 1급 및 2급 히드록실기를 산화 반응시켜 하기 화학식 10의 화합물을 수득하는 단계;
(viii) 하기 화학식 10의 화합물을 하기 화학식 11의 화합물과 위티그(wittig) 반응시켜 하기 화학식 12의 화합물을 수득하는 단계; 및
(ix) 하기 화학식 12의 화합물을 Pd/C에서 수소 하에 수소화 및 탈보호화 반응시키는 단계를 포함하는 하기 화학식 1의 루비프로스톤의 제조방법:
[화학식 2]
[화학식 3]
[화학식 4]
[화학식 5]
[화학식 6]
[화학식 7]
[화학식 8]
[화학식 9]
[화학식 10]
[화학식 11]
[화학식 12]
[화학식 1]
상기 식에서,
Bz은 벤조일기이고,
Ac는 아세틸기이며,
R 및 Bn은 벤질기이다.(i) deprotecting a compound of formula (2) in the presence of a base to obtain a compound of formula (3);
(ii) reacting a compound of formula (3) with vinyl acetate in the presence of a lipase to selectively protect a primary hydroxyl group to obtain a compound of formula (4);
(iii) reacting a compound of formula (4) with benzyl chloromethyl ether to protect the secondary hydroxyl group to obtain a compound of formula (5);
(iv) reducing the ketone of the compound of formula (5) and simultaneously deprotecting the protecting group of the primary hydroxyl group to obtain a compound of formula (6);
(v) subjecting a compound of formula (6) to a Wittig reaction with a compound of formula (7) to obtain a compound of formula (8);
(vi) reacting a compound of formula 8 with benzyl bromide to protect the carboxylic acid group to give a compound of formula 9;
(vii) oxidizing the primary and secondary hydroxyl groups of the compound of formula (9) to obtain a compound of formula (10);
(viii) subjecting a compound of formula (10) to a Wittig reaction with a compound of formula (11) to obtain a compound of formula (12); And
(ix) hydrogenating and deprotecting a compound of formula (12) below under hydrogenation at Pd / C to produce a rubyprostone of formula (1)
(2)
(3)
[Chemical Formula 4]
[Chemical Formula 5]
[Chemical Formula 6]
(7)
[Chemical Formula 8]
[Chemical Formula 9]
[Chemical formula 10]
(11)
[Chemical Formula 12]
[Chemical Formula 1]
In this formula,
Bz is a benzoyl group,
Ac is an acetyl group,
R and Bn are benzyl groups.
[화학식 5]
상기 식에서,
Ac는 아세틸기이고,
R은 벤질기이다.Compounds of formula 5:
[Chemical Formula 5]
In this formula,
Ac is an acetyl group,
R is a benzyl group.
(ii) 하기 화학식 3의 화합물을 리파아제의 존재 하에 비닐 아세테이트와 반응시켜 1급 히드록실기를 선택적으로 보호하여 하기 화학식 4의 화합물을 수득하는 단계; 및
(iii) 하기 화학식 4의 화합물을 벤질 클로로메틸 에테르와 반응시켜 2급 히드록실기를 보호하는 단계를 포함하는 하기 화학식 5의 화합물의 제조방법:
[화학식 2]
[화학식 3]
[화학식 4]
[화학식 5]
상기 식에서,
Bz은 벤조일기이고,
Ac는 아세틸기이며,
R은 벤질기이다.(i) deprotecting a compound of formula (2) in the presence of a base to obtain a compound of formula (3);
(ii) reacting a compound of formula (3) with vinyl acetate in the presence of a lipase to selectively protect a primary hydroxyl group to obtain a compound of formula (4); And
(iii) a step of reacting a compound of the following formula (4) with benzyl chloromethyl ether to protect the secondary hydroxyl group:
(2)
(3)
[Chemical Formula 4]
[Chemical Formula 5]
In this formula,
Bz is a benzoyl group,
Ac is an acetyl group,
R is a benzyl group.
(v) 하기 화학식 6의 화합물을 하기 화학식 7의 화합물과 위티그(wittig) 반응시켜 하기 화학식 8의 화합물을 수득하는 단계;
(vi) 하기 화학식 8의 화합물을 벤질 브로마이드와 반응시켜 카복실산기를 보호하여 하기 화학식 9의 화합물을 수득하는 단계;
(vii) 하기 화학식 9의 화합물의 1급 및 2급 히드록실기를 산화 반응시켜 하기 화학식 10의 화합물을 수득하는 단계;
(viii) 하기 화학식 10의 화합물을 하기 화학식 11의 화합물과 위티그(wittig) 반응시켜 하기 화학식 12의 화합물을 수득하는 단계; 및
(ix) 하기 화학식 12의 화합물을 Pd/C에서 수소 하에 수소화 및 탈보호화 반응시키는 단계를 포함하는 하기 화학식 1의 루비프로스톤의 제조방법:
[화학식 5]
[화학식 6]
[화학식 7]
[화학식 8]
[화학식 9]
[화학식 10]
[화학식 11]
[화학식 12]
[화학식 1]
상기 식에서,
Ac는 아세틸기이고,
R 및 Bn은 벤질기이다.(iv) reducing the ketone of the compound of formula (5) and simultaneously deprotecting the protecting group of the primary hydroxyl group to obtain a compound of formula (6);
(v) subjecting a compound of formula (6) to a Wittig reaction with a compound of formula (7) to obtain a compound of formula (8);
(vi) reacting a compound of formula 8 with benzyl bromide to protect the carboxylic acid group to give a compound of formula 9;
(vii) oxidizing the primary and secondary hydroxyl groups of the compound of formula (9) to obtain a compound of formula (10);
(viii) subjecting a compound of formula (10) to a Wittig reaction with a compound of formula (11) to obtain a compound of formula (12); And
(ix) hydrogenating and deprotecting a compound of formula (12) below under hydrogenation at Pd / C to produce a rubyprostone of formula (1)
[Chemical Formula 5]
[Chemical Formula 6]
(7)
[Chemical Formula 8]
[Chemical Formula 9]
[Chemical formula 10]
(11)
[Chemical Formula 12]
[Chemical Formula 1]
In this formula,
Ac is an acetyl group,
R and Bn are benzyl groups.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140177425A KR20160070457A (en) | 2014-12-10 | 2014-12-10 | Process for Preparing Lubiprostone and Intermediate Therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140177425A KR20160070457A (en) | 2014-12-10 | 2014-12-10 | Process for Preparing Lubiprostone and Intermediate Therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160070457A true KR20160070457A (en) | 2016-06-20 |
Family
ID=56354299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140177425A Withdrawn KR20160070457A (en) | 2014-12-10 | 2014-12-10 | Process for Preparing Lubiprostone and Intermediate Therefor |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20160070457A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019131510A (en) * | 2018-01-31 | 2019-08-08 | 協和ファーマケミカル株式会社 | Method of producing lubiprostone |
| JP2020011956A (en) * | 2018-07-13 | 2020-01-23 | チャイロゲート インターナショナル インク.Chirogate International Inc. | Lubiprostone crystal and method for its preparation |
-
2014
- 2014-12-10 KR KR1020140177425A patent/KR20160070457A/en not_active Withdrawn
Non-Patent Citations (4)
| Title |
|---|
| 미국 특허 제5,252,605호 |
| 미국 특허 제5,284,858호 |
| 미국 특허 제7,355,064호 |
| 미국 특허 제7,812,182호 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019131510A (en) * | 2018-01-31 | 2019-08-08 | 協和ファーマケミカル株式会社 | Method of producing lubiprostone |
| JP2020011956A (en) * | 2018-07-13 | 2020-01-23 | チャイロゲート インターナショナル インク.Chirogate International Inc. | Lubiprostone crystal and method for its preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101732477B1 (en) | Processes and intermediates for the preparations of isomer free prostaglandins | |
| JP5485980B2 (en) | Process for producing prostaglandin analogues and intermediates thereof | |
| KR102027889B1 (en) | Process for the preparation of travoprost | |
| JP2012519163A (en) | Method for producing prostaglandin derivative | |
| KR101787159B1 (en) | Processes for preparation of lubiprostone | |
| KR20160070457A (en) | Process for Preparing Lubiprostone and Intermediate Therefor | |
| JPS62187485A (en) | Production of 24,25-epoxycholesterol or such | |
| RU2702355C1 (en) | Method of producing pyrimidinylcyclopentane compounds | |
| JP2013234194A (en) | Method of producing c-glycoside derivative | |
| CA2544560C (en) | Processes for preparing bicyclo [3.1.0] hexane derivatives, and intermediates thereto | |
| KR100457732B1 (en) | The preparation of asymmetric furofuranelignan compound | |
| JPH0592963A (en) | Preparation of 2,5-diaryl tetrahydrofurans and analogs thereof useful as paf antagonist | |
| KR20130114074A (en) | Preparation of tesetaxel and related compounds and corresponding synthesis intermediate | |
| JP2008037782A (en) | Method for producing prostaglandine derivative | |
| JP7164901B2 (en) | Process for producing latanoprosten-bunod and its intermediates, and compositions containing them | |
| KR20220011502A (en) | Novel preparing method of inotodiol | |
| WO2013164729A1 (en) | An improved and scalable process for preparation of prostaglandin derivatives and intermediates thereof | |
| EP2643326B1 (en) | Process for the preparation of (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]furan-3-ol | |
| Wang et al. | The Efficient Synthesis of the Optically Active β‐Hydroxyl‐γ‐butyrolactone Derivatives | |
| JP2004107315A (en) | Method for producing hexahydrofurofuranol derivative, its intermediate and method for producing the same | |
| JP3020980B2 (en) | Optically active valerolactone derivative | |
| JP2893473B2 (en) | Process for producing (+)-equilenin and intermediate | |
| JP2002513732A (en) | An intermediate for acetogenin in Annelidae | |
| CN105801534B (en) | A kind of key intermediate preparing limaprost and its application | |
| JP4591778B2 (en) | Process for producing α, β, γ-substituted cyclopentanone derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20141210 |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |